Chinese healthcare stocks are back in vogue after a $142 billion wipeout, as signs grow that the worst of a government crackdown is over.
The Hang Seng Composite Healthcare Index, dominated by Chinese companies, has rallied 11% in the past month, having plunged 37% from a January peak after Beijing launched an anti-graft clampdown on the pharmaceutical sector.
Read the full story here.